WO2000003747A2 - Odontostomatologic use of apatite-based nanostructured materials - Google Patents
Odontostomatologic use of apatite-based nanostructured materials Download PDFInfo
- Publication number
- WO2000003747A2 WO2000003747A2 PCT/IT1999/000224 IT9900224W WO0003747A2 WO 2000003747 A2 WO2000003747 A2 WO 2000003747A2 IT 9900224 W IT9900224 W IT 9900224W WO 0003747 A2 WO0003747 A2 WO 0003747A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apatite
- dentine
- gel
- use according
- materials
- Prior art date
Links
- 229910052586 apatite Inorganic materials 0.000 title claims abstract description 54
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 title claims abstract description 52
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 19
- 210000004268 dentin Anatomy 0.000 claims abstract description 71
- 239000000463 material Substances 0.000 claims abstract description 62
- 210000005239 tubule Anatomy 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 201000002170 dentin sensitivity Diseases 0.000 claims abstract description 31
- 239000000243 solution Substances 0.000 claims abstract description 29
- 210000003298 dental enamel Anatomy 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000004568 cement Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000000606 toothpaste Substances 0.000 claims abstract description 6
- 230000007547 defect Effects 0.000 claims abstract description 5
- 239000000499 gel Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 24
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 20
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 20
- 239000011575 calcium Substances 0.000 claims description 17
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- 235000011006 sodium potassium tartrate Nutrition 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 150000001450 anions Chemical group 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 10
- 239000001639 calcium acetate Substances 0.000 claims description 10
- 235000011092 calcium acetate Nutrition 0.000 claims description 10
- 229960005147 calcium acetate Drugs 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 9
- 229940074439 potassium sodium tartrate Drugs 0.000 claims description 8
- 239000006072 paste Substances 0.000 claims description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 5
- 229910001427 strontium ion Inorganic materials 0.000 claims description 5
- 229940034610 toothpaste Drugs 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229940051866 mouthwash Drugs 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 241000700159 Rattus Species 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 229910000497 Amalgam Inorganic materials 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 claims description 2
- 210000003074 dental pulp Anatomy 0.000 claims description 2
- 239000000565 sealant Substances 0.000 claims description 2
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229940045110 chitosan Drugs 0.000 claims 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- FLASNYPZGWUPSU-SICDJOISSA-N chitosan Chemical class O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H](O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](N)[C@H]2O)CO)[C@H](N)[C@H]1O)CO)NC(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N FLASNYPZGWUPSU-SICDJOISSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 15
- 239000002707 nanocrystalline material Substances 0.000 abstract description 11
- 230000002950 deficient Effects 0.000 abstract description 4
- 230000009257 reactivity Effects 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 37
- 239000002253 acid Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000035699 permeability Effects 0.000 description 16
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 208000002599 Smear Layer Diseases 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000021317 phosphate Nutrition 0.000 description 11
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000003239 periodontal effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- -1 Sr2+ ions Chemical class 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 239000000551 dentifrice Substances 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000005470 impregnation Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 235000001055 magnesium Nutrition 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000013081 microcrystal Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 229960001714 calcium phosphate Drugs 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 229910052587 fluorapatite Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940085991 phosphate ion Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000004434 Calcinosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HECLRDQVFMWTQS-UHFFFAOYSA-N Dicyclopentadiene Chemical compound C1C2C3CC=CC3C1C=C2 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000009388 chemical precipitation Methods 0.000 description 2
- 238000005229 chemical vapour deposition Methods 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 238000005240 physical vapour deposition Methods 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 2
- 229960002799 stannous fluoride Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 229940047908 strontium chloride hexahydrate Drugs 0.000 description 2
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- ZCLVNIZJEKLGFA-UHFFFAOYSA-H bis(4,5-dioxo-1,3,2-dioxalumolan-2-yl) oxalate Chemical compound [Al+3].[Al+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O ZCLVNIZJEKLGFA-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- DRTSMJJTVBYBPG-UHFFFAOYSA-L calcium;carbonic acid;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [Ca+2].[O-]C([O-])=O.OP(O)(F)=O DRTSMJJTVBYBPG-UHFFFAOYSA-L 0.000 description 1
- KBQXDPRNSDVNLB-UHFFFAOYSA-L calcium;carbonic acid;hydrogen phosphate Chemical compound [Ca+2].OC(O)=O.OP([O-])([O-])=O KBQXDPRNSDVNLB-UHFFFAOYSA-L 0.000 description 1
- GFIKIVSYJDVOOZ-UHFFFAOYSA-L calcium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [Ca+2].[O-]P([O-])(F)=O GFIKIVSYJDVOOZ-UHFFFAOYSA-L 0.000 description 1
- 230000000248 cariostatic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 210000002531 dentinal fluid Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000003178 glass ionomer cement Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002488 metal-organic chemical vapour deposition Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001451 molecular beam epitaxy Methods 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004416 odontoblast Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000000016 photochemical curing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229940093928 potassium nitrate Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000001089 thermophoresis Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/15—Compositions characterised by their physical properties
- A61K6/17—Particle size
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/52—Cleaning; Disinfecting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/54—Filling; Sealing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
- A61K6/74—Fillers comprising phosphorus-containing compounds
- A61K6/75—Apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/849—Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Definitions
- the present invention concerns the use in odontostomatology of apatite-based nanostructured materials. More specifically, the invention concerns the application in the fields of dentistry and dental hygiene of biocompatible crystalline products based on apatite with high specific surface properties, having single constituent crystals of nanometric size. Such products are particularly useful in the treatment of dentine hypersensitivity and in the remineralisation of dental tissue.
- dentine sensitivity or hypersensitivity is a complex symptomatology, characterised by pain and sensitivity to thermal, mechanical (i.e. tactile), chemical and osmotic stimuli caused by exposure of the dentin to the oral environment.
- Several data on the epidemiology of dentine hypersensitivity have been published in the latest years, revealing, inter alia, that such clinical condition affects more than 15% of the population in the age range between 20 and 40 years, with a particular preference for females.
- Dentine hypersensitivity may be primary, i.e. not resulting from any therapeutic intervention on the dental components, or it may be secondary to previous periodontal interventions and/or to injuries resulting in dentine exposure, or to restorations (including dental prostheses) with projecting margins or having an incorrect shape. After an extensive periodontal intervention, especially of resective surgery, patients quite frequently report a hypersensitivity not previously present. In such cases the affection is also referred to as radicular or cervical hypersensitivity.
- Such displacement is induced by mechanical stimuli (such as, for instance, by passing the speculum over the tooth surface), by osmotic and chemical stimuli (such as by the contact with food, beverages, etc.) and by thermal stimuli (both hot and, specially, cold).
- mechanical stimuli such as, for instance, by passing the speculum over the tooth surface
- osmotic and chemical stimuli such as by the contact with food, beverages, etc.
- thermal stimuli both hot and, specially, cold
- the exposed dentine behaves as a semi-permeable membrane, wherein the dentine tubules represent the membrane pores. Therefore, the diameter and number of the exposed tubules largely affect the degree of sensitivity, as it has been ascertained in vivo by Yoshiyama et al. (M. Yoshiyama, Y. Noiri, K. Oaki, A. Uchida, Y. Ishikawa, H. Ishida, Transmission electron microscopic characterisation of hypersensitive human radicular dentin, J. Dent. Res.; 69: 1293-1297 (1990)).
- any dental treatment involving the removal of enamel and dentine, and thus the opening of the dental tubules unavoidably results in an increased sensitivity.
- the patient with dentine hypersensitivity is found to have, at the same time, an area of exposed dentine (i.e., an area deprived of enamel and/or of gum covering) with open tubular orifices, and no kind of surface debris or smear layer (the latter term actually meaning the layer of debris that normally covers the dentine and closes the tubules with plugs, i.e. the so-called smear plugs) obstructing, at least partially, the dentine tubules.
- Food may play a primary role in causing the onset or, more properly, the becoming acute again, of dentine hypersensitivity.
- several food items or beverages have acid properties, as they contain citric, phosphoric or maleic acid, and they may easily effect the chemical removal of the surface smear layer, thus opening the dentine tubules.
- other food items or beverages such as red wine, citrus fruits and unripe fruits in general, have been reported to have effects on the dentine hypersensitivity.
- a particular situation may occur in patients who have undergone a resective periodontal intervention, about 80% of whom reports dentine sensitivity after the periodontal therapy.
- Periodontal procedures may be related to the occurrence of dentine hypersensitivity: for instance, during the operative procedures of dental calculus removal, root scalling, root planning, root polishing and surface cleaning, any residual cement (which is often already absent) and any infected dentine are removed, thus resulting in the removal of large root surfaces and in the exposure of an extremely high number of open dentine tubules.
- any residual cement (which is often already absent) and any infected dentine are removed, thus resulting in the removal of large root surfaces and in the exposure of an extremely high number of open dentine tubules.
- the passage of intratubular fluid from the interior of the pulp cavity to the exterior thereof with loss of plasma proteins and electrolytes, and, vice- versa
- the passage of liquid and toxins from the exterior of the pulp cavity to the interior thereof a temporary pulpitis occurs, accompanied by a painful symptomatology. The latter is normally felt after some hours or days from the intervention.
- the symptoms spontaneously decrease owing to the spontaneous obstruction of the tubules, resulting from the deposition of bacterial debris, the precipitation of proteins and fibrinogen and the production of a smear layer by the patient himself during the normal dental hygiene procedures with the toothbrush (Pashley, 1990, loc. cit).
- dentifrices containing strontium chloride hexahydrate The most studied and well-known products for home therapy include dentifrices containing strontium chloride hexahydrate.
- the latter as pointed out in the foregoing, is used in view of its ability of closing the dentine tubules, rather than for its activity in depressing the dentinal nerve fibres stimulation. It is believed that the Sr 2+ ion reacts with the apatite matrix of the dentine, thus forming with said matrix an insoluble strontium-apatite. The latter settles as a layer of microcrystals, that are able to reduce the functional diameter of the dentine tubules. Also stannous fluoride is believed to act by forming insoluble complexes with dentine (i.e.
- dentifrices and desensitising preparations have been proposed, which, rather than being based on products that form insoluble precipitates by reacting in the oral environment, are based on the direct use of apatite, i.e., the basic material making up the dentine, in the microcrystalline state.
- apatite i.e., the basic material making up the dentine
- the US patent No. 4634589 discloses the use of a crystalline apatite having a particle size of less than 8 ⁇ m as an abrasive and polishing agent, active in the treatment of dentine hypersensitivity and also having a remineralising action on the dental tissue.
- the dentifrice formulation proposed contains at least 15% by weight of such ingredient.
- the European patent application No. 0346957 discloses the use of hydroxyapatite as a desensitising abrasive agent for dental products.
- the hydroxyapatite particle size is 1-15 ⁇ m
- the formulation proposed also comprises a source of potassium and/or strontium (as a further desensitising agent).
- dentine hypersensitivity by home therapy, however, has the drawback of requiring long periods of time (often more than four weeks) to reach any appreciable clinical results. In addition, the said results are often only partial, as a great amount of co-operation is required from the patient.
- the treatment of dentine hypersensitivity is preferably carried out at the dentist's consulting room, by directly treating the affected tooth (or teeth). Also in this case, the main aim is to occlude the open dentine tubules. Several techniques and materials have been proposed to that aim, according to the degree of seriousness of the symptoms.
- Such techniques can be schematically divided into four main groups: 1 ) mechanical treatment of the sensitive surface in order to obtain a new smear layer; 2) application of agents effective in occluding the dentinal tubules, either directly or by forming insoluble precipitates; 3) impregnation and obstruction of the dentine tubules by means of adhesives; 4) application of dental restoration materials, optionally together with intraoral devices for sustained release of fluorine.
- the dental restoration and the endodontal treatment are often included in order to finally solve the problem.
- the adoption of the above treatment is limited to non serious cases, e.g. to treat patients after a periodontal intervention with exposure of limited dentine surfaces and without any previous history of dentine hypersensitivity.
- the second kind of medical treatment mentioned in the foregoing consists, for instance, in applying oxalates (such as potassium, iron or aluminium oxalate, and oxalic acid) on the affected dentine surface.
- oxalates such as potassium, iron or aluminium oxalate, and oxalic acid
- Such agents may react with the dentinal apatite constituents, thus forming insoluble calcium oxalate microcrystals on the surface and in the interior of the dentine tubules.
- the solutions containing the concerned agent may easily be applied on the dentine surface by means of little brushes, and they may be left in situ for 2-3 minutes, this period of time being enough for the said microcrystals to form. It is to be noted, however, that this technique may involve some problems due to the toxicity of oxalates. Also silver nitrate, another agent em- ployed for a long time for the same purpose, has a mechanism of action based on the formation of precipitates (Ag chloride) which occlude the dentine tubules.
- precipitates Ag chloride
- the same kind of therapeutic approach also includes the direct application of microcrystalline apatite, as mentioned in the foregoing in connection with products for home therapy.
- the medical treatment includes the use of an ultramicronised apatite, such as that disclosed, for instance, in the Italian patent No. 1271874, where the particle size of about 70% of the apatite microcrystals is less than 1 ⁇ m (0.2-1 ⁇ m).
- Such product is considered to be more active than the micronised apatite products disclosed in the foregoing, on the basis of the simple consideration that the dentine tubules have an average diameter of about 1.3-3.5 ⁇ m.
- the resin by penetrating into the tubules, forms long plugs (referred to as resin tags) which occlude the tubular lumen and reduce the dentine per- meability.
- the resin impregnates and occludes the small lateral channels as well (as it has recently been confirmed by some studies by scanning electron microscopy), thus contributing to the formation of a thick resin network effective in stably blocking any movement of the dentine fluid.
- a hybrid layer made of resin and collagen is thus formed. From the point of view of the mechanism of action, it is not clear whether other factors co-operate in reducing the sensitivity, in addition to the tubules occlusion and the consequent permeability reduction (which is, very likely, the main mechanism of action).
- the said amorphous salts, or solutions that may originate such salts by precipitation are applied on the dental tissue surface, and settle thereon and within the same tissue.
- the amorphous salts are then converted to crystalline apatite, thus performing a remineralising action and reducing dentine sensitivity.
- the PCT patent application No. WO 94/04460 (American Dental Association Health Foundation) also presents the ACCPF phosphate (i.e., amorphous calcium carbonate fluorophosphate), as a new compound particularly interesting for the same purpose.
- the apatite materials characterised by a nanocrystalline and/or defective structure lend themselves much better to the objects men- tioned above, as they allow to achieve remarkable therapeutic results, up to the complete suppression of dentine hypersensitivity and, in addition, with a considerable remineralisation of the dental tissue.
- Such results are made possible by the unique features of the crystalline nanostructures, that substantiate the great potential of these advanced materials in many applicative fields.
- the nanocrystalline materials are artificially synthesised materials, characterised by a constituent phase, or by granular structures, modulated on a length scale normally smaller than 100 nm.
- the nano- crystalline materials are considered to be with dimensionality equal to zero (clusters of atoms - for instance, dispersed in a non-nanocrystalline matrix , filaments or tubules), with dimensionality one (multilayers, i.e., layers which are nanometric in the only direction of the thickness), with dimensionality two (granular superpositions, ultrafine, or buried layers), or with dimensionality three (nanophasic materials, wherein all of the constituent phases are of nanometric proportions on three dimensions) (R.W.
- the basis of the particular performances of the nanostructured materials is to be found in the fact that a physical property of matter becomes altered when the entity or the mechanism responsible for such property (or the combination thereof) are confined within a space (defined by the dimension of the atoms set) smaller than a given critical length associated with such entity or mechanism. Therefore, for instance, a metal that is conventionally ductile owing to the usual ease in creating and displacing dislocations through the crystal lattice thereof will become remarkably harder when the grain size is reduced down to a criti- cal point wherein the dislocation sources are no more able to work at the low levels of the applied stress.
- the nanocrystalline materials are also characterised by the high number of interfaces they contain. Since the number of interfaces present in the nanocrystalline materials is much higher than in the conventional materials, a suitable control, in the course of the synthesis, on the nature of the interfaces created between the constituent phases leads to a control on the nature of the interactions through the said interfaces. In order to have an idea of the importance of the interface environment in a nanocrystal- line material it is sufficient to consider, for instance, that in a material with an average grain size of 5-10 nm the percentage of atoms comprised in the grain boundaries is in the range from 15 to 50%.
- the apatite-based nanostructured materials appear to possess, firstly, the most suitable granular dimensions to easily and deeply penetrate within the dentine tubules (which, as pointed out before, have diameters in the range of 1.3-3.5 ⁇ m).
- the concerned materials show specific physico-chemical properties connected with their nanocrystalline nature, such as the remarkable surface chemical reactivity and the hygroscopicity, which not only allow the material to penetrate mechanically within the tubules, but also cause it to cement the internal surfaces thereof, both by swelling and by readily reacting with the natural tissue, and recrystallising as a result of the metastable character of the nanocrystalline system.
- the latter may have, in this specific case, a high defective content.
- Apatite-based materials characterised by a nanocrystalline structure appear to have somehow been described, so far, only in the PCT patent application No. WO 97/17285 (Etex Corp.), concerning the low temperature synthesis of a low crystallinity apatite for use in bone tissue graft.
- the definition of "low crystallinity material” given in such text generically includes both amorphous materials and nanocrystalline materials (with nanometre- sized or Angstrom-sized crystalline domains).
- Such document exclusively concerns the production of resorbable synthetic bone materials, which, in view of their intended use, are formed in moulds to give solid elements.
- the only relevant requirement for such use is the ability of closely reproducing the natural bone tissues, so that the synthetic bone graft is inte- grated and resorbed in the said tissues.
- the applications of the concerned material in the orthopaedic field differ from the odontostomatological application in that in the first case the material must comply with stability requirements, it must be able to easily integrate within the bone and, in some cases, it must be able to induce bone growth (direct relationship between material and cells), while in the second case the material must interact with mineral tissue having chemical and structural properties different from bone, and having a different organic component. Consequently, in the latter case character- istics of the material such as surface reactivity and metastability will have to prevail.
- the orthopaedic applications that involve interventions on the bone tissue are concerned with a system interacting with the blood stream and unaffected by variations induced by the contact with the external envi- ronment (such as pH changes or compositional variations of various kinds). This is right the opposite of what happens in the oral environment, and on the tooth surface.
- the present invention specifically provides the use of apatite-based nanostructured materials of the general formula: Ca 10- ⁇ M x (P ⁇ 4)6-yByA 2 (OH) 2-z wherein M is a cation different from Ca 2+ , B is an anion different from P0 4 3 ⁇ , A is chosen from the group consisting of O 2 ", CO 3 2 ", F” and Cl", x is a number from 0 to 9, y is a number from 0 to 5, z is a number from 0 to 2, wherein the said numbers may also be fractional, with the proviso that the sum of the charges of the Ca and M cations is equal to the sum of the charges of the P0 4 3_ , B, A, and OH" anions, having average size of the crystallites comprised between 0.5 and 200 nm, for the production of preparations for odontostomatologic applications, useful for the restoration and the protection of dental tissue and, specifically, for the therapy of dentine hypersensitivity and for the
- apatites represent the main inorganic process of calcification of normal tissue (i.e. enamel, dentine, cement, bone) and are found associated with other phosphatic and non-phosphatic minerals in pathological calcifications.
- normal tissue i.e. enamel, dentine, cement, bone
- phosphatic and non-phosphatic minerals in pathological calcifications.
- hydroxyapatite or hy- droxylapatite having the stoichiometric formula Ca- ⁇ 0 (P ⁇ 4 ) 6 (OH) 2 (or Ca 5 (P0 2 ) 3 ⁇ H), and being - in its synthetic (biocompatible) form - the apatite material most widely exploited at a commercial level for several indications in dentistry, orthopaedy and maxillo-facial surgery, is never found in a pure state in the biological tissues. This is due to the possible isomorphous replacements of the Ca 2+ , PO 4 3 - and OH " ions.
- the calcium ion may be totally or partially replaced by a number of cations generally (but not exclusively) having oxidation number +2;
- the phosphate ion (site B) may be replaced by carbonate, acid phosphate, pyrophosphate, sulphate, aluminate and silicate ions, and the hydroxyl ion (site A) may be replaced by halogenide, carbonate and oxide ions.
- biological apatites have a Ca/P molar ratio comprised between 1.53 and 1.74 (in particular, comprised between 1.53 and 1.64 for the dental enamel, between 1.62 and 1.68 for the dentine and between 1.72 and 1.80 for the bone).
- the oscillations in the Ca/P ratio may be caused by: 1 ) lattice vacancies; 2) ions isomorphically replaced or adsorbed on the lattice surface (for instance, the substitution of the P0 4 3_ anion with acid phosphate, which is divalent, brings about a reduction in the calcium contents); 3) coexistence or presence of possible precursors consisting of phosphates with different Ca/P ratio.
- ⁇ -tricalcium phosphate i.e. Ca 3 (P0 4 ) 2
- an orthophosphate also known as tribasic calcium phosphate
- ACP amorphous calcium phosphate
- OCP octocalcium phosphate
- DCPD dicalcium phosphate dihydrate
- DCPD CaHP0 4 -2H2 ⁇ , also known as calcium acid phosphate, dibasic calcium phos- phate or dicalcium orthophosphate.
- the Ca/P molar ratio values for some of the phosphates considered are as follows: HA Ca 5 (P0 4 ) 3 OH 1.67 OCP Ca 8 H 2 (P04) 6 -5H 2 0 1.33
- biological apatites may be described as non-stoichio- metric carbonatoapatites containing, in general as impurities, different ions. For this reason, biological apatites have variable morphology, crystalline charac- teristics, chemical and phisico-chemical properties.
- hydroxyapatite [Ca 5 (P ⁇ ) 3 ⁇ H] has already been presented as the most widespread material.
- the phosphate and calcium ions are placed approximately according to a hexagonal prism; in the direction of elongation (crystallographic axis c) the prism is crossed by a channel having a diameter of 3-3.5 A, housing any OH" groups or other possible replacing ions (e.g., fluorine and chlorine).
- HA may crystallise in two forms: a monocline form (spatial group P2 1 /b) and a hexagonal form (spatial group P6 3 /m).
- a monocline form a binary symmetry axis is present along the axis c, while in the hexagonal form the symmetry axis becomes hexagonal.
- OCP octocalcium phosphate
- HA octocalcium phosphate
- the Mg 2+ ions inhibit the hydroxyapatite precipitation and promote the formation of ⁇ -tricalcium phosphate.
- the magne- sium concentration exceeds 10% the simultaneous formation of HA and ⁇ - TCP occurs, the latter being the only product that precipitates when the concentration exceeds 25%.
- the fact that magnesium replaces calcium in ⁇ -TCP is made evident by the displacement of the X-ray diffraction peaks in the powder diffraction spectra of the same samples.
- the magnesium contents in biological apatites is very low
- Strontium is present in biological apatites only at the impurity level, and may replace calcium, thus causing an expansion of the a and c axes.
- the presence of this element in apatites for odontostomatological use is considered to be important in connection with a possible cariostatic effect thereof (in addition to the hypothesised effect of reduction of the dentine sensitivity), and confers on the apatite a lower solubility and a higher resistance to thermal treatments.
- this cation does not isomorphically replace calcium in the whole concentration interval.
- the variation of the lattice parameters results in an expansion of the cell parameters.
- hydroxyapatite may also be substituted with anionic groups.
- the carbonate ion may replace the hydroxyl ion (site A) or the phosphate ion (site B) or both.
- site A hydroxyl ion
- site B phosphate ion
- the replacement of the carbonate ion in the site B is prefer- ential in the biological samples, it is also possible to obtain carbonatoapatites of the type A synthetically, by means of high temperature reactions.
- carbonatoapatites of the type B or mixed type A + B are mainly obtained by precipitation from solutions.
- the presence of the carbonate ion in hydroxyapatite modifies the lattice dimensions: if the said ion occupies the A site an increase in the a parameter is obtained, as a consequence of the greater size of the C0 3 2_ ion with respect to the OH" ion; if, on the contrary, the carbonate ion occupies the B site the same parameter undergoes a contraction, due to the smaller 0-0 distance in the CO 3 2 - ion with respect to the PO 4 3 - ion.
- Fluoroapa- tite is characterised by an increase in the crystal dimensions, by a decrease in the a parameter of the unit cell, by a lower solubility and by an enhanced thermal stability.
- the lower solubility, and therefore the higher lattice stability, of the fluoroapatites substantiates the present use of the fluoride ion in the therapy of bone affections and of dental caries.
- Chloroapatite is characterised by an expansion of the a side and a contraction of the c side of the unit cell.
- the different lattice behaviour of chlo- roapatite with respect to fluoroapatite derives from the remarkable difference in ionic radius between the two halogens: in fluoroapatites the fluoride ion is placed on the senary axis located on the plane defined by the three calcium ions, while in chloroapatites the chloride ion is slightly displaced from the plane of the metal ions. This phenomenon results in the above-mentioned parameter variations of chloroapatite, while the crystallinity does not seem to be significantly affected, even if the thermal stability decreases.
- the non-stoichiometric character of biological apatites may also be caused by the presence of the acid phosphate ion HPO 4 2 -; this ion is contained specifically in the tooth enamel, in amounts comprised between 5% and 15%, and is effective in increasing the hydroxyapatite solubility.
- the presence of acid phosphate in biological and synthetic apatites is not easily detectable, since the carbonate ion, which is almost always present, overlaps the I.R. absorption bands and causes a similar variation of the cell parameters.
- the original presence of HP0 4 2 " may be evidenced by the pyrophosphate formation, obtained by heating the apatite samples between 400 e 500°C.
- the M cation is chosen among the following ones: H + , Na + , Mg 2+ , K + , Sr 2+ , Ba 2+ and Fe 2+ , and preferably the x value is comprised between 0 and 2.
- the B anion is chosen, preferably, among C ⁇ 3 2 ⁇ , HP0 2 ⁇ , HC0 3 " , and P2O7 4" , while the y value may be comprised, for instance, between 0 and 2.
- the nanostructured apatites according to the invention may be produced by any one of the several known methods, already in use for the production of nanocrystalline materials, such as the synthesis methods from atomic or molecular precursors (e.g., chemical or physical vapour deposition, condensation in gas, chemical precipitation, reactions from aerosol), the methods of production from mass precursors (e.g. by mechanical attrition, by crystallisation from the amorphous state, by phase separation), and the methods borrowed from nature (i.e., biologically mimicked systems).
- atomic or molecular precursors e.g., chemical or physical vapour deposition, condensation in gas, chemical precipitation, reactions from aerosol
- mass precursors e.g. by mechanical attrition, by crystallisation from the amorphous state, by phase separation
- the methods borrowed from nature i.e., biologically mimicked systems.
- the conventional deposition of layers of material by electrolytic processes or by vapour condensation has been exploited in recent times to deposit materials of nanometric dimensions with remarkable control and
- the new or improved methods include, in particular, increasingly advanced mono- or multi-bath systems for electrodeposition and new chemical or physical vapour deposition methods, such as molecular beam epitaxy (MBE), metal-organic chemical vapour deposition (MOCVD) and chemical vapour synthesis (CVS).
- MBE molecular beam epitaxy
- MOCVD metal-organic chemical vapour deposition
- CVS chemical vapour synthesis
- the synthesis of nanocrystalline materials by in situ consolidation, under vacuum, of ultrafine particles condensed in the form of nanometre-sized gas starts when a precursor material, be it an element or a compound, is evaporated into a gas maintained under low pressure, generally well below 1 atmosphere.
- a precursor material be it an element or a compound
- the evaporated atoms loose energy as a result of the collisions with the atoms or mole- cules of the gas, and undergo a homogeneous condensation suitable to form clusters of atoms in the highly supersaturated area close to the precursor source.
- the nanometre-sized grains form a nucleus within slip bands of highly deformed precursors materials, thus transforming a coarse-grained structure into a nanophasic one.
- a great deformation is normally obtained by means of a high energy crushing, but it may also occur as a consequence of surface wear phenomena (E. Hellstern, H.J. Fecht, Z. Fu and W.L. Johnson., J. Appl. Phys., 65 (1989); C.C. Koch, Nanostructured Mater., 2, 109 (1993)), or it may be obtained through other methods of introduction of high deformation densities (R. Valiev, in Mechanical Properties and Deformation Behaviour of Materials Having Ultra-Fine Microstructures, M. Nastasi, D.M. Parkin, and H. Gleiter. 303 (1993)). In the course of the hard mechanical work on the precursors it is also possible to react different materials so as to have them form new phases and compounds.
- the method has been used for the synthesis of the nanostructured apatite materials according to the invention that underwent the comparative experimentation described further on.
- the nanostructured apatite material according to the invention was produced starting from apatite with microcrystalline structure through lattice de- stabilisation in a controlled environment, under high energy, by subjecting the starting material to a high mechanical energy transfer treatment. The latter is carried out into a cylindrical reaction chamber by means of high energy impacts from hard balls contained within the same chamber.
- the kinetic energy of the balls is generated by a rotation movement of the chamber with respect to its main axis and by a revolution movement of the same with respect to an axis parallel to the main one.
- the transformation of kinetic energy into mechanical energy of lattice destabilisation occurs through impacts between the balls and the starting material.
- the chamber may work either in air or in inert gas or under vacuum, down to a pressure value of 10 "6 torr, or with liquids (alcohol, ethers, oils and other organic molecules).
- the above method reduces the crystallites dimension through subsequent introduction of lattice defects (which may be evaluated by means of X- ray diffraction techniques).
- the nanoapatite material obtained by the disclosed synthesis method and employed in the applications reported herein shows an average dimension of the crystallites of about 15 nm, with an average strain ranged between 10 "5 and 10 "2 .
- the apatite-based nanocrystalline products according to the present invention represent a material that simulates the dentine composition and is perfectly compatible, both biologically and structurally, with the dental tissue. The material is able to efficiently become stably integrated with the dentine, thus making it totally impermeable.
- the dimensional features, the properties of surface activity and the defective contents of the nanoapatites allow to easily obtain both the mechanical filling of the tubules and the fixing reaction with the tubule surface (i.e. remineralisation). Therefore, the dentine sensitivity resulting from the hydraulic conductivity through the tubule structure of dentine is practically removed.
- the said permeability is a critical factor in the dentinal pain stimulation theory, as the presence of exposed and open tubules causes, when suitable external stimuli are present, the movement of dentinal fluid, perceived at the neural structure level as a pain stimulus.
- the nanocrystal- line apatite materials are protected from acid attack by subjecting them to a treatment with protective aqueous solutions containing tartaric acid and/or its salts, such as, e.g., aqueous solutions containing potassium sodium tartrate (or Seignette's salt, or Rochelle's salt, NaOOC(CHOH) 2 COOK-4H 2 0) and hydrous calcium acetate (Ca(CH 3 COO) 2 -H 2 0), or, in the alternative, with a solution containing tartaric acid (HOOC(CHOH) 2 COOH).
- protective aqueous solutions containing tartaric acid and/or its salts such as, e.g., aqueous solutions containing potassium sodium tartrate (or Seignette's salt, or Rochelle's salt, NaOOC(CHOH) 2 COOK-4H 2 0) and hydrous calcium acetate (Ca(CH 3 COO) 2 -H 2 0), or, in the alternative, with
- a 0.1-1.0 M solution of potassium sodium tartrate and a 0.1-1.0 M solution of hydrous calcium acetate are used in a sequence, by dipping therein the material according to the invention, preferably at 37°C, for periods of time comprised between 5 and 30 minutes. Specifically, the nanoapatite is immersed in the first solution and kept therein for 5 minutes, then it is withdrawn from the first solution and immediately immersed in the second solution for 20-30 minutes.
- the material can also be individually treated with one of the following agents: mono-, bi-, tri-, tetra-, polycarboxylated calcium gluconate in aqueous solution at a concentration of 0.01-5% by weight, or in alcoholic or hydroalco- holic solution at a concentration in the range from 0.01% and 15% by weight; or with an acetic and/or malic and/or hyaluronic solution of chitosan at a con- centration in the range from 5% to 20% by weight; or with a solution of human, bovine, swine, rat or turkey tendon collagen, either isotonic or not, at a concentration in the range from 0.5% to 5% by weight.
- agents mono-, bi-, tri-, tetra-, polycarboxylated calcium gluconate in aqueous solution at a concentration of 0.01-5% by weight, or in alcoholic or hydroalco- holic solution at a concentration in the range from 0.01% and 15% by weight;
- the said treatments result in a protection of the nanostructured material from acid environments.
- the said material may also be used without any further treatment.
- the invention further concerns compositions for odontostomatologic use comprising the apatite-based nanostructured materials described in the foregoing, together with further possible ingredients and excipients of the same kind as those used in preparations for dental hygiene and for the therapy of the oral cavity.
- the compositions that are preferably in the form of toothpaste, paste, gel, suspension or solution, preferably contain from 0.5% to 50% by weight of nanocrystalline apatite material, either treated with protective agents or not.
- Further preferred features of the compositions according to the invention, with particular reference to oral formulations in the gel form are specified in the further dependent claims.
- EXAMPLE 1 A microcrystalline carbonate-apatite material, non-stoichiometric as regards the hydroxy ion, was subjected to a lattice destabilisation treatment in a controlled environment, under high energy, by using the reaction chamber described in the foregoing.
- the resulting product (nanoapatite) is characterised by average crystallite sizes of 15-20 nm and by an average microstrain content comprised between 10 "4 and 10 "5 .
- nanoapatite 1 or nano 1 A portion of the nanocrystalline apatite thus obtained (which will be referred to in the following as nanoapatite 1 or nano 1 ) has also been sub- jected to treatment with tartrate in order to increase its resistance to acid attack in the conditions of use in the oral cavity.
- the nanoapatite was treated with a 0.1 M aqueous solution of potassium sodium tartrate (Sei- gnette's salt, Carlo Erba, Milano) at 37°C for 5 minutes, and then with a 0.1 M solution of hydrous calcium acetate (Carlo Erba, Milano) at 37°C for 20 minutes.
- EXAMPLE 2 An apatite material of the same nature and composition as the material of Example 1 was subjected to a similar lattice destabilisation treatment, with a different value of the energetic content transferred. The resulting nanoapatite was characterised by average crystallite dimensions of 10-14 nm and by an average microstrain content comprised between 5-10 "4 and 10 "4 .
- nanocrystalline apatite thus obtained (i.e. nanoapatite 2 or nano 2) was treated with potassium sodium tartrate and hydrous calcium acetate, according to the same procedure of Example 1.
- the effectiveness of the nanocrystalline apatite products according to the invention in the treatment of dentine hypersensitivity was evaluated in terms of reduction of the hydraulic conductance within the dentine tubules, according to a well established protocol (Pashley, 1990, loc. cit), in agreement with the international literature.
- sound human molars have been used, extracted for orthodontic reasons from young patients, in order to avoid the problem of sclerotic dentine.
- Each crown was properly separated from the root and cut in order to obtain a crown segment deprived of the occlusal enamel. After removing the pulp tissue, the crown segment was fixed by means of adhesive onto a Plexiglas base, with the flat surface of occlusal dentine facing upwards.
- the base was crossed through its entire thickness by a tubular stainless steel segment, projecting into the pulp cavity in order to provide the hydraulic connection, below the Plexiglas base, with the hydraulic conductance measuring device.
- the latter was made of a simple hydrodynamic device consisting of a set of capillary tubes filled with deionised water and connected through the tubular stainless steel segment to the pulp cavity. The passage of water from the pulp cavity to the occlusal surface through the dentine was evidenced by the displacement of an air bubble in a graduated microcapillary tube located in the hydrodynamic sys- tern.
- nanoapatite 1 produced according to Example 1 ; 5. nanoapatite 1 treated with potassium sodium tartrate and hydrous calcium acetate according to Example 1 ;
- the permeability tests were performed seven times for each of the set times (30, 60, 120 seconds) after treatment with each single gel, and repeating each stage of the above procedure.
- Nanoapatite 1 62.28 64.47 64.11 100.00 44.40 35.92 32.85 47.67 41.63 38.40
- Nanoapatite 1 treated 63.31 67.13 65.19 100.00 42.92 37.09 33.02 37.91 33.93 34.02
- Nanoapatite 2 treated 64.11 62.96 63.37 100.00 39.89 34.45 30.67 38.18 32.18 30.81
- microcrystalline hydroxyapatite may bring about a partial occlusion of the dentine tubules, with reduced permeability in comparison with the smear layer formation step.
- H3PO4 no detectable resistance is noted.
- microcrystalline hydroxyapatite is treated with the Seignette's salt and calcium acetate solutions.
- the behaviour before and after acid attack, with or without the protective treatment, is evident from the enclosed histogram.
- nanoapatites 1 and 2 the dentine permeability is greatly reduced, to the point that the permeability falls from 100% after treatment with EDTA to about 40% after treatment with the nanoapatites, and further improves up to 120 seconds. In this case, even the acid attack does not result in any appreciable negative effect, this being certainly the most interesting data.
- nanocrystalline apatite according to the invention is even more evident when nanoapatites treated with Seignette's salt and calcium acetate are used. These not only produce a remarkable reduction in the dentine permeability in the absence of an acid at- tack, but, most remarkably, afford an even more considerable reduction after the final acid attack by H 3 PO 4 , with permeability values not exceeding about 35% of the value after treatment with EDTA.
- nanoapatite 2 gave a lower standard deviation in the measurements, and therefore a greater reproducibiiity in the results.
- the nanostructured apatite materials according to the invention can be validly proposed as biocompatible materials having a marked and prolonged action in reducing the hydraulic conductance within the dentine tubules, and suitable to become stably and deeply integrated in the dentine tissue.
- the said materials may advantageously be employed, either as such or included in powder, toothpaste, paste, gel, solutions, mouth- wash, suspensions, tablet, capsule, resin or cement compositions, in preparations for the protection of dentine, for the therapy of dentine hypersensitivity, for the remineralisation of enamel, dentine, dental tissues and supporting tissues, for the closure of dentine tubules or the reduction of their functional diameter, for the protection of dental pulp and of prosthetic abutments, as well as in preparations for use as bases and liners for dental restorations with amalgam, as cements for endodontic fillings and for dental prostheses, and as orthodontic cements and sealants for enamel and dentine.
- the present invention has been disclosed with particular reference to some specific embodiments thereof, but it should be understood that modifications and changes may be made by the persons skilled in the art without departing from the scope of the invention as defined in the appended claims.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51919/99A AU5191999A (en) | 1998-07-17 | 1999-07-16 | Odontostomatologic use of apatite-based nanostructured materials |
EP99936957A EP1098623A2 (en) | 1998-07-17 | 1999-07-16 | Odontostomatologic use of apatite-based nanostructured materials |
CA002338021A CA2338021A1 (en) | 1998-07-17 | 1999-07-16 | Odontostomatologic use of apatite-based nanostructured materials |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM98A000476 | 1998-07-17 | ||
IT98RM000476A IT1299563B1 (en) | 1998-07-17 | 1998-07-17 | ODONTOSTOMATOLOGICAL USE OF NANOSTRUCTURED APATITIC BASED MATERIALS |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000003747A2 true WO2000003747A2 (en) | 2000-01-27 |
WO2000003747A3 WO2000003747A3 (en) | 2000-05-11 |
Family
ID=11406050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT1999/000224 WO2000003747A2 (en) | 1998-07-17 | 1999-07-16 | Odontostomatologic use of apatite-based nanostructured materials |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1098623A2 (en) |
AU (1) | AU5191999A (en) |
CA (1) | CA2338021A1 (en) |
IT (1) | IT1299563B1 (en) |
WO (1) | WO2000003747A2 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001001930A2 (en) * | 1999-07-02 | 2001-01-11 | Henkel Kommanditgesellschaft Auf Aktien | Composite materials comprised of calcium compounds and protein constituents |
WO2001095863A2 (en) * | 2000-06-16 | 2001-12-20 | Henkel Kommanditgesellschaft Auf Aktien | Compositions for treating tooth and/or bone tissue |
WO2002049578A1 (en) * | 2000-12-20 | 2002-06-27 | Henkel Kommanditgesellschaft Auf Aktien | Remineralising dental adhesive film |
WO2002069986A1 (en) * | 2001-03-06 | 2002-09-12 | Rutgers, The State University | Magnesium-substituted hydroxyapatites |
EP1335887A1 (en) * | 2000-10-16 | 2003-08-20 | University Of South Carolina | Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement |
WO2004047785A1 (en) | 2002-11-26 | 2004-06-10 | The Procter & Gamble Company | Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth |
US6887488B2 (en) | 2000-05-19 | 2005-05-03 | Tsinghua University | Nano-calcium phosphates/collagen based bone substitute materials |
WO2005110339A1 (en) * | 2004-05-18 | 2005-11-24 | S & C Polymer, Silicon- Und Composite Spezialitäten Gmbh | Composition containing nano-crystalline apatite |
WO2006133747A1 (en) * | 2005-06-15 | 2006-12-21 | Henkel Kommanditgesellschaft Auf Aktien | Remineralizing oral and dental care and cleansing compositions |
WO2007137606A1 (en) * | 2006-05-30 | 2007-12-06 | Coswell S.P.A. | Biologicallly active nanoparticles of a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same |
US7649029B2 (en) | 2004-05-17 | 2010-01-19 | 3M Innovative Properties Company | Dental compositions containing nanozirconia fillers |
US7998219B2 (en) | 2005-01-04 | 2011-08-16 | Rutgers, The State University Of New Jersey | Hydroxyapatite with controllable size and morphology |
EP2409677A1 (en) * | 2009-03-19 | 2012-01-25 | Southcoast Dental Co., Ltd. | Tooth surface repairing material |
WO2012159645A1 (en) | 2011-05-26 | 2012-11-29 | Coswell S.P.A. | Dental care products comprising carbonate-substituted fluoro-hydroxyapatite particles |
EP2591825A1 (en) * | 2011-11-08 | 2013-05-15 | PeGoMa B.V. | Composition for the treatment of teeth, and use |
WO2013068020A1 (en) | 2011-11-08 | 2013-05-16 | Coswell S.P.A. | Dental care products containing biomimetic hydroxyapatite particles having a lactoferrin-functionalized surface |
WO2014027887A2 (en) | 2012-08-13 | 2014-02-20 | Matthew Scott Spaid | Teeth whitening composition |
US8815328B2 (en) | 2005-01-04 | 2014-08-26 | Rutgers, The State University Of New Jersey | Hydroxyapatite with controllable size and morphology |
CN104254336A (en) * | 2012-02-10 | 2014-12-31 | 派瑞达克有限公司 | Multicomponent oral care composition |
WO2015078950A1 (en) | 2013-11-29 | 2015-06-04 | Perfetti Van Melle S.P.A. | Confectionary products with calcium phosphate |
EP3053570A4 (en) * | 2013-09-30 | 2017-05-24 | Kuraray Noritake Dental Inc. | One-component-type dentinal tubule sealant |
RU2627624C1 (en) * | 2016-10-06 | 2017-08-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Means for teeth hard tissue remineralization |
WO2017178824A1 (en) * | 2016-04-14 | 2017-10-19 | M B Lloyd Limited | A dental formulation for the treatment of tooth sensitivity |
WO2020138422A1 (en) | 2018-12-27 | 2020-07-02 | シライシ カルシウム(シンガポール) プライベート リミテッド | Hydroxyapatite particulate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323632A1 (en) * | 1987-12-28 | 1989-07-12 | Asahi Kogaku Kogyo Kabushiki Kaisha | Composition for forming calcium phosphate type setting material and process for producing setting material |
IT1271874B (en) * | 1994-03-07 | 1997-06-09 | Massimo Minozzi | ADDITION OF HYDROXYAPATITE, CA10 (PO4) 6 (OH) 2, ULTRAMICRONIZED, HAUM, DIAMETER OF MICROCRYSTALS: OR, 2 - 1, OR MICRON, RANGE 70% TO THE VARIOUS TYPES OF CANAL CONCRETE FOR THE FINAL FILLING OF THE ROOT CANALS OF THE TOOTH . |
EP0786245A1 (en) * | 1996-01-24 | 1997-07-30 | Sangi Co., Ltd. | Dental compositions containing submicrometer hydroxyapatite |
WO1997041273A1 (en) * | 1996-04-30 | 1997-11-06 | Flametal S.P.A. | Process for the preparation of hydroxyapatite coatings |
EP0832636A2 (en) * | 1996-09-30 | 1998-04-01 | Degussa Aktiengesellschaft | Polymerisable dental material and use of apatite fillers in the dental material |
WO1998016268A2 (en) * | 1996-10-16 | 1998-04-23 | Etex Corporation | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
-
1998
- 1998-07-17 IT IT98RM000476A patent/IT1299563B1/en active IP Right Grant
-
1999
- 1999-07-16 EP EP99936957A patent/EP1098623A2/en not_active Withdrawn
- 1999-07-16 AU AU51919/99A patent/AU5191999A/en not_active Abandoned
- 1999-07-16 WO PCT/IT1999/000224 patent/WO2000003747A2/en not_active Application Discontinuation
- 1999-07-16 CA CA002338021A patent/CA2338021A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0323632A1 (en) * | 1987-12-28 | 1989-07-12 | Asahi Kogaku Kogyo Kabushiki Kaisha | Composition for forming calcium phosphate type setting material and process for producing setting material |
IT1271874B (en) * | 1994-03-07 | 1997-06-09 | Massimo Minozzi | ADDITION OF HYDROXYAPATITE, CA10 (PO4) 6 (OH) 2, ULTRAMICRONIZED, HAUM, DIAMETER OF MICROCRYSTALS: OR, 2 - 1, OR MICRON, RANGE 70% TO THE VARIOUS TYPES OF CANAL CONCRETE FOR THE FINAL FILLING OF THE ROOT CANALS OF THE TOOTH . |
EP0786245A1 (en) * | 1996-01-24 | 1997-07-30 | Sangi Co., Ltd. | Dental compositions containing submicrometer hydroxyapatite |
WO1997041273A1 (en) * | 1996-04-30 | 1997-11-06 | Flametal S.P.A. | Process for the preparation of hydroxyapatite coatings |
EP0832636A2 (en) * | 1996-09-30 | 1998-04-01 | Degussa Aktiengesellschaft | Polymerisable dental material and use of apatite fillers in the dental material |
WO1998016268A2 (en) * | 1996-10-16 | 1998-04-23 | Etex Corporation | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
Non-Patent Citations (3)
Title |
---|
ATSUSHI N ET AL: "Synthesis and sintering behavior of hydroxyapatite by chemical process" COMPENDEX / EIX97353729434,1997, XP002131868 * |
DE GROOT ET AL: "Morphology and composition of nanograde calcium phosphate needle-like crystals formed by simple hydrothermal treatment" JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE, vol. 5, no. 6-7, July 1994 (1994-07), pages 326-331, XP002131869 London, England * |
WANG R Z ET AL: "Synthesis of nanophase hydroxyapatite/collagen" JOURNAL OF MATERIALS SCIENCE LETTERS, vol. 14, no. 7, 1 April 1995 (1995-04-01), XP002131870 London, England * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001001930A3 (en) * | 1999-07-02 | 2001-07-12 | Henkel Kgaa | Composite materials comprised of calcium compounds and protein constituents |
WO2001001930A2 (en) * | 1999-07-02 | 2001-01-11 | Henkel Kommanditgesellschaft Auf Aktien | Composite materials comprised of calcium compounds and protein constituents |
EP1676555A3 (en) * | 1999-07-02 | 2009-06-17 | Henkel AG & Co. KGaA | Composite materials comprised of calcium compounds and protein constituents |
US6887488B2 (en) | 2000-05-19 | 2005-05-03 | Tsinghua University | Nano-calcium phosphates/collagen based bone substitute materials |
WO2001095863A2 (en) * | 2000-06-16 | 2001-12-20 | Henkel Kommanditgesellschaft Auf Aktien | Compositions for treating tooth and/or bone tissue |
WO2001095863A3 (en) * | 2000-06-16 | 2002-03-28 | Henkel Kgaa | Compositions for treating tooth and/or bone tissue |
DE10028975B4 (en) * | 2000-06-16 | 2005-06-30 | Henkel Kgaa | Compositions for the treatment of tooth and / or bone tissue |
US7081161B2 (en) | 2000-10-16 | 2006-07-25 | University Of South Carolina | Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using cement |
EP1335887A1 (en) * | 2000-10-16 | 2003-08-20 | University Of South Carolina | Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement |
EP1335887A4 (en) * | 2000-10-16 | 2004-06-23 | Univ South Carolina | Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement |
US7527687B2 (en) | 2000-10-16 | 2009-05-05 | University Of South Carolina | Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement |
WO2002049578A1 (en) * | 2000-12-20 | 2002-06-27 | Henkel Kommanditgesellschaft Auf Aktien | Remineralising dental adhesive film |
WO2002069986A1 (en) * | 2001-03-06 | 2002-09-12 | Rutgers, The State University | Magnesium-substituted hydroxyapatites |
US6921544B2 (en) | 2001-03-06 | 2005-07-26 | Rutgers, The State University | Magnesium-substituted hydroxyapatites |
US7704529B2 (en) | 2001-03-06 | 2010-04-27 | Richard E Riman | Magnesium-substituted hydroxyapatites |
US8337904B2 (en) | 2001-03-06 | 2012-12-25 | Rutgers, The State University Of New Jersey | Magnesium-substituted hydroxyapatites |
WO2004047785A1 (en) | 2002-11-26 | 2004-06-10 | The Procter & Gamble Company | Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth |
US7649029B2 (en) | 2004-05-17 | 2010-01-19 | 3M Innovative Properties Company | Dental compositions containing nanozirconia fillers |
WO2005110339A1 (en) * | 2004-05-18 | 2005-11-24 | S & C Polymer, Silicon- Und Composite Spezialitäten Gmbh | Composition containing nano-crystalline apatite |
US8815328B2 (en) | 2005-01-04 | 2014-08-26 | Rutgers, The State University Of New Jersey | Hydroxyapatite with controllable size and morphology |
US7998219B2 (en) | 2005-01-04 | 2011-08-16 | Rutgers, The State University Of New Jersey | Hydroxyapatite with controllable size and morphology |
WO2006133747A1 (en) * | 2005-06-15 | 2006-12-21 | Henkel Kommanditgesellschaft Auf Aktien | Remineralizing oral and dental care and cleansing compositions |
US8367043B2 (en) | 2006-05-30 | 2013-02-05 | Coswell S.P.A. | Biologically active nanoparticles a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same |
WO2007137606A1 (en) * | 2006-05-30 | 2007-12-06 | Coswell S.P.A. | Biologicallly active nanoparticles of a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same |
JP5506782B2 (en) * | 2009-03-19 | 2014-05-28 | ブライトスマイルジャパン株式会社 | Tooth surface restoration material |
KR20120022781A (en) * | 2009-03-19 | 2012-03-12 | 가부시끼가이샤 소프세라 | Tooth surface repairing material |
EP2409677A1 (en) * | 2009-03-19 | 2012-01-25 | Southcoast Dental Co., Ltd. | Tooth surface repairing material |
EP2409677A4 (en) * | 2009-03-19 | 2013-02-13 | Britesmilejapan Co Ltd | Tooth surface repairing material |
KR101581075B1 (en) | 2009-03-19 | 2015-12-29 | 가부시끼가이샤 소프세라 | Tooth surface repairing material |
US9433569B2 (en) | 2011-05-26 | 2016-09-06 | Coswell S.P.A. | Dental care products comprising carbonate-substituted fluoro-hydroxyapatite particles |
WO2012159645A1 (en) | 2011-05-26 | 2012-11-29 | Coswell S.P.A. | Dental care products comprising carbonate-substituted fluoro-hydroxyapatite particles |
WO2013068495A3 (en) * | 2011-11-08 | 2013-09-26 | Pegoma B.V. | Composition for the treatment of teeth, and use |
WO2013068020A1 (en) | 2011-11-08 | 2013-05-16 | Coswell S.P.A. | Dental care products containing biomimetic hydroxyapatite particles having a lactoferrin-functionalized surface |
EP2591825A1 (en) * | 2011-11-08 | 2013-05-15 | PeGoMa B.V. | Composition for the treatment of teeth, and use |
JP2014532671A (en) * | 2011-11-08 | 2014-12-08 | コズウェル・エス・ペー・アーCoswell S.P.A. | Dental care products containing biomimetic hydroxyapatite particles with a lactoferrin functionalized surface |
US9408788B2 (en) | 2012-02-10 | 2016-08-09 | Periproducts Ltd | Multicomponent oral care composition |
JP2015506971A (en) * | 2012-02-10 | 2015-03-05 | ペリプロダクツ リミテッド | Multi-component oral care composition |
EP3207934A1 (en) * | 2012-02-10 | 2017-08-23 | Periproducts Ltd | Multicomponent oral care composition |
US9211240B2 (en) | 2012-02-10 | 2015-12-15 | Periproducts Ltd | Multicomponent oral care composition |
CN104254336A (en) * | 2012-02-10 | 2014-12-31 | 派瑞达克有限公司 | Multicomponent oral care composition |
WO2014027887A2 (en) | 2012-08-13 | 2014-02-20 | Matthew Scott Spaid | Teeth whitening composition |
WO2014027887A3 (en) * | 2012-08-13 | 2014-10-23 | Matthew Scott Spaid | Teeth whitening composition |
EP3053570A4 (en) * | 2013-09-30 | 2017-05-24 | Kuraray Noritake Dental Inc. | One-component-type dentinal tubule sealant |
US9962319B2 (en) | 2013-09-30 | 2018-05-08 | Kuraray Noritake Dental Inc. | One-component-type dentinal tubule sealant |
WO2015078950A1 (en) | 2013-11-29 | 2015-06-04 | Perfetti Van Melle S.P.A. | Confectionary products with calcium phosphate |
WO2017178824A1 (en) * | 2016-04-14 | 2017-10-19 | M B Lloyd Limited | A dental formulation for the treatment of tooth sensitivity |
GB2554484A (en) * | 2016-04-14 | 2018-04-04 | M B Lloyd Ltd | A dental formulation for the treatment of tooth sensitivity |
GB2554484B (en) * | 2016-04-14 | 2021-07-07 | M B Lloyd Ltd | A dental formulation for the treatment of tooth sensitivity |
RU2627624C1 (en) * | 2016-10-06 | 2017-08-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) | Means for teeth hard tissue remineralization |
WO2020138422A1 (en) | 2018-12-27 | 2020-07-02 | シライシ カルシウム(シンガポール) プライベート リミテッド | Hydroxyapatite particulate |
Also Published As
Publication number | Publication date |
---|---|
IT1299563B1 (en) | 2000-03-16 |
EP1098623A2 (en) | 2001-05-16 |
WO2000003747A3 (en) | 2000-05-11 |
ITRM980476A0 (en) | 1998-07-17 |
AU5191999A (en) | 2000-02-07 |
CA2338021A1 (en) | 2000-01-27 |
ITRM980476A1 (en) | 2000-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000003747A2 (en) | Odontostomatologic use of apatite-based nanostructured materials | |
Suge et al. | Effects of fluoride on the calcium phosphate precipitation method for dentinal tubule occlusion | |
KR101258976B1 (en) | Biologically active nanoparticles of a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same | |
JP5816352B2 (en) | Method for producing dentin hypersensitivity inhibitor | |
EP2812010B1 (en) | Multicomponent oral care composition | |
EP2626058B1 (en) | Dentinal tubule sealant and method for producing the same | |
Ishikawa et al. | Occlusion of dentinal tubules with calcium phosphate using acidic calcium phosphate solution followed by neutralization | |
WO2008068149A1 (en) | Oral care product | |
CA2017918A1 (en) | Fluoride colloid and oral composition | |
Abdelnabi et al. | Effect of different formulations and application methods of coral calcium on its remineralization ability on carious enamel | |
US9005587B2 (en) | Anti-bacterial and mineralizing calcium phosphate compositions | |
US20220296477A1 (en) | Stabilized amorphous calcium magnesium phosphate particle compositions | |
EP3473235A1 (en) | Composition of materials for tooth remineralisation | |
EP2713992B1 (en) | Dental care products comprising carbonate-substituted fluoro-hydroxyapatite particles | |
Seyedlar et al. | Synthesis of plate-like β-tricalcium phosphate nanoparticles and their efficiency in remineralization of incipient enamel caries | |
RU2426690C2 (en) | Biologically active nanoparticles of carbonate-substituted hydroxyapatite, method of their production and compositions that include them | |
Degli Esposti et al. | Composite materials of amorphous calcium phosphate and bioactive glass nanoparticles for preventive dentistry | |
Omran et al. | Assessment of Remineralizing Effect of Bioactive Glass Based Toothpastes: an In-Vitro Comparative Study | |
US20050123490A1 (en) | Composition and method for prevention and treatment of dental caries | |
WO2023163647A1 (en) | Amorphous calcium magnesium fluoride phosphate particles | |
Duminis et al. | In vitro hydroxyapatite formation of a TTCP and DCPA based dentine desensitiser | |
WO2021048041A1 (en) | Oral care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2338021 Country of ref document: CA Ref country code: CA Ref document number: 2338021 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743973 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999936957 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999936957 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999936957 Country of ref document: EP |